July 26, 2016 08:45 AM EDT
R&D

J&J joins the com­bo line­up at Bris­tol-My­ers, where a new wag­on mas­ter runs on­col­o­gy R&D

John Carroll

Editor & Founder

J&J is tak­ing an im­muno-on­col­o­gy drug li­censed in from Aduro and match­ing it with Bris­tol-My­ers Squibb’s pi­o­neer­ing check­point drug Op­di­vo in the lat­est ex­am­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times